Review of Extraosseous Applications of Thermal Ablation in the Treatment of Moderate to Severe Large Joint Osteoarthritis

Andrew Tran, BS1 David A. Reiter, PhD2 J. David Prologo, MD3 Mircea Cristescu, MD3 Felix M. Gonzalez, MD3

1 Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia
2 Department of Radiology and Imaging Sciences, and Orthopedics, Emory University School of Medicine, Atlanta, Georgia
3 Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia

Address for correspondence Felix M. Gonzalez, MD, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA (e-mail: felix.m.gonzalez@emory.edu).


Abstract

Osteoarthritis (OA) is the most common joint disease worldwide, leading to significant pain, restricted range of motion, and disability. A gap exists between short- and long-term symptom-relieving therapies. Although arthroplasty is an effective treatment for symptomatic end-stage disease, most patients ultimately do not receive a joint replacement due to suboptimal surgical qualifications, comorbidities, or an aversion to surgery. The lack of additional treatment options in this setting makes opioid agonists a commonly used pharmacologic agent, contributing to the addiction epidemic that greatly afflicts our communities. Cooled radiofrequency ablation (CRFA) has arisen as a treatment modality in the setting of moderate to severe OA among patients refractory to conservative management, generally showing greater efficacy compared with other existing strategies. This review focuses on the benefits of CRFA and its technical feasibility as a management option among patients experiencing debilitating large joint OA with limited clinical options.

Keywords
► cooled radiofrequency ablation
► arthritis
► hip
► knee
► shoulder

Osteoarthritis (OA) is the most common disease process of the large joints, involving ~650 million adults >40 years of age worldwide as of 2020.1 The pathophysiology involves degeneration of articular cartilage, the connective tissue responsible for transmitting load across joints. This is accompanied by irreversible bony remodeling: osteophyte overgrowth, subchondral plate thickening, and severe chondral wear. The annual financial impact for caring for this disease, including earnings lost for adults, was reported to have reached >$300 billion in 2013.2 Because OA is a disease associated with aging and metabolic disease, increases in OA-related costs are anticipated as people live longer and as obesity rates continue to climb.3,4

Patients with OA usually present with chronic pain, limited range of motion, and muscle weakness. The typical radiologic signs are joint space narrowing, cyst formation, osteophytes, and subchondral sclerosis. OA typically affects the knee and hip, but it can also significantly affect the shoulder, as seen in 32.8% of cadaveric and radiologic studies in patients >60 years of age.5 The clinical management for OA ranges from activity modification, to intra-articular injection, to surgery. Intra-articular anesthetic corticosteroid injections are aimed to reduce joint inflammation and pain, with a large variation in efficacy ranging from 1 to 24 weeks.6 Long treatment durations of corticosteroid injections were also associated with chondrotoxicity, worsening disease progression.7,8 Patients eventually turn to surgery for long-lasting pain relief; however, arthroplasty may have complications such as infection, failed implants, and...
continued joint pain. The longevity of hip and knee implants was estimated as 58% and 82% at 25-year follow-up, respectively.\textsuperscript{9} The primary symptom of OA is joint pain that can exist beyond curative surgery.\textsuperscript{10} Joint pain persists beyond 3 to 5 months in 20% of patients after knee replacement surgery and 10% of patients after hip replacement surgery.\textsuperscript{11} Thermal neurolysis has evolved as an alternative method of treating the arthritic symptoms among patients who are not surgical candidates for joint replacement or who are experiencing postoperative pain without hardware complications or infection.

Neurolysis, which disrupts pain signal transmissions, is a way to mitigate pain from advanced OA or postsurgical pain. Thermal radiofrequency ablation (TRFA) is a relatively novel treatment method that uses radiofrequency probes to ablate these nerves at temperatures \textgreek{t} 80 to \textgreek{t} 90°C.\textsuperscript{12} CRFA (cooled radiofrequency ablation) is a type of TRFA but considered more effective because it delivers a greater ablative zone, accounting for the anatomical variability of nerve branches. CRFA has already been used to treat knee pain and shown improved joint function and decreased dependence on pain medication for up to 2 years in patients with knee OA.\textsuperscript{13–15} Here we review the literature that describes thermal neurolysis, and specifically CRFA, in the treatment of knee, hip, and shoulder osteoarthrosis as well as describe the procedural techniques used in our clinic.

**Knee Osteoarthritis**

Knee OA accounts for 83% of all OA cases.\textsuperscript{16} Symptomatic knee OA was estimated to affect >27 million U.S. adults.\textsuperscript{17} Risk factors that contribute to knee OA include obesity, diabetes, previous knee trauma (by 3.86 times), old age, and muscle weakness. OA accounts for most knee pain, followed by nondegenerative diseases like posttraumatic, postsurgical, patellofemoral pain syndromes and meniscal, tendon, and ligament injuries.\textsuperscript{18} Of all patients with OA, 66% are obese, and most of the obese patients report that their joint pain prevents them from losing weight.\textsuperscript{19} Common clinical symptoms of knee OA are persistent knee pain, morning stiffness, and reduced function.\textsuperscript{20,21} Patients may have crepitus and painfully limited range of motion. Knee OA pain is typically located anywhere from the distal femur to the proximal tibia. It progressively worsens and is exacerbated with prolonged activity or repetitive bending.\textsuperscript{22}

Management for knee OA predominantly addresses pain with the goal to improve function and range of motion. Nonoperative treatment options include activity modification, weight loss, orthotics, medical treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), hyaluronic acid (HA), corticosteroid, and platelet-rich plasma injections. Nonsurgical treatments such as education, exercise, insoles, weight loss, and pain medications were effective in reducing knee pain in knee OA patients at 3 months.\textsuperscript{23} NSAIDs were proven to reduce knee pain by 12% on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale to 6 months for patients who had an 8-year mean duration of OA.\textsuperscript{24} However, many patients use NSAIDs only when needed, rather than continuously, and it is not an ideal sole treatment for knee pain.

Weight loss with unsupervised exercises described in the Look AHEAD study were proven to reduce pain and significantly improve physical function in diabetic overweight and obese adults with knee pain at 12 months.\textsuperscript{25–27} For many patients, though, weight loss is a strenuous process that requires time and resources, to which many patients do not have access. In a prospective study, knee braces significantly improved knee pain at 26 weeks in patients with knee OA (\textgreek{p} < 0.05).\textsuperscript{28} However, knee braces can be tedious to apply and maintain. Slightly more invasive procedures for knee OA are corticosteroid injections, which have few systemic adverse events. However, a 2015 Cochrane review concluded that, compared with placebo, clinical benefits of knee corticosteroid injections after 1 week are unclear due to low evidence.\textsuperscript{29}

Total knee arthroplasty (TKA) is the most invasive treatment for OA and one of the most common procedures performed in the United States, averaging 500,000 procedures a year in North America.\textsuperscript{30} Patients who received TKA had significantly greater Knee Injury and OA Outcome Scores (meaning better pain relief) at 12 months, compared with patients who were treated nonsurgically via exercise, insoles, and pain medication.\textsuperscript{31} Skou et al also found a significantly greater number of adverse effects in the TKA group (24 TKA patients versus 6 nonsurgical patients, of 95 total patients) than in the nonsurgical group, with complications such as soft tissue infections, postsurgical stiffness, deep vein thromboses, and chronic pain.\textsuperscript{31} With the rise in obesity rates in the past few decades, knee OA cases will continue to climb, and more patients will need TKAs and pain management.\textsuperscript{32,33}

**Technique**

The most widespread application of CRFA to the knee targets three genicular nerve branches: the superolateral (SL), superomedial (SM), and inferomedial (IM) genicular nerves (\textsuperscript{►}Fig. 1). Recent evidence suggests that additional ablation of the medial retinacular (MR) branch results in significantly greater improvement in knee OA pain at 6 months (\textgreek{p} = 0.004), compared with ablation of only the three genicular nerve branches (\textsuperscript{►}Fig. 1).\textsuperscript{15,34}

**Diagnostic Nerve Block Procedure**

Approximately 3 to 4 weeks before the CRFA procedure, patients undergo diagnostic genicular nerve blocks under fluoroscopic or, less frequently, ultrasonographic (US) guidance to determine their candidacy for CRFA. Patients lie supine on a fluoroscopic table with the symptomatic knee flexed at 30 degrees. Then, 1 to 2 mL lidocaine is injected superficially at each of the injection sites, and 25G or 22G spinal needles are inserted, targeting the concave transitions of the femoral metaphysis and condyles for the SL and SM genicular nerves; the IM genicular nerve is targeted by inserting a spinal needle at the concave transition between the tibial plateau and metadiaphyseal shaft (\textsuperscript{►}Fig. 2).\textsuperscript{15} For patients who undergo the fourth nerve block, the needle is...
positioned at the midline anterior distal femoral diaphysis 3 cm cephalad to the superior patella (Fig. 3). For each site, 1.0 mL 1% or 2% lidocaine or 0.25% bupivacaine is injected. Patients are then assessed after 15 minutes, and if they report at least 50% of pain reduction during physical examination and ambulation, they are considered candidates for CRFA.

**Radiofrequency Ablation Procedure**

Patients arrive for the CRFA procedure 2 to 3 weeks later, and informed consent is obtained. Patients lie supine on the fluoroscopy table, and moderate sedation is achieved with 1 to 2 mg intravenous (IV) midazolam or 25 to 100 μg IV fentanyl, as needed. Patients are provided with supplemental oxygen via nasal cannula, and vitals are monitored throughout the procedure. To ensure adequate conduction of the CRFA, a grounding pad is placed ipsilateral to the target joint, avoiding major scar tissue, bony prominences, metal prostheses, electrocardiogram (EKG) electrodes, and areas of possible edema. Then 1 to 2 mL 2% lidocaine is superficially injected at each target site for CRFA.

**Fig. 1** Schematic illustration showing the respective locations of the genicular nerves around the knee. The three-needle technique uses the introducer needles, targeting the superomedial femoral (SM), superolateral (SL) femoral, and inferomedial (IM) tibial genicular nerves. In the four-needle technique, an additional needle is placed ~ 3 cm proximal to the patella to target the medial retinacular nerve (MR).

**Fig. 2** Three-needle approach targeting the respective genicular nerve locations on the anteroposterior (left) and lateral (right) views. On the lateral view, the guide needles cover at least 50% of the bone shaft width.
The sites for CRFA are similar to the sites used for the diagnostic genicular nerve block. The 17G introducer needles are placed at the SM, SL, MR, and IM nerve locations (►Figs. 2 and 3). An 18G RFA electrode (4mm active tip) is inserted into the introducer needle, and position is confirmed with anteroposterior (AP) and lateral fluoroscopic views. Motor nerve activity is tested and excluded. Local anesthesia with 1 mL 2% lidocaine is injected into the introducer needle. Each nerve is then ablated for 180 seconds at 60°C.

**Efficacy of CRFA for Treating Knee OA Pain**

Multiple studies have assessed the efficacy of CRFA in alleviating knee pain secondary to OA. Bellini and Barbieri reported the first nine cases and found significant improvement in perceived pain 1 month after treatment. The baseline visual analog scale (VAS) mean score was 8.0 ± 1.5 and decreased to 2 ± 0.5 at 1 month posttreatment and to 2.2 ± 0.2 at 12 months posttreatment. A noticeable improvement in function was also noted with the WOMAC mean score at baseline, which was 88 ± 1.9 at baseline, decreased to 20 ± 2 at 1 month and 12 months (20 ± 1.0). One of the latest retrospective reviews of 275 geniculate nerve block patients reported a significant decrease of the VAS score from 8.5 to 4.2 after CRFA. In this cohort, 65% of patients claimed > 50% pain relief lasting up to 12.5 months, and 77% of patients had a decrease of ≥ 2 VAS points 6 months after CRFA. However, case reports and retrospective studies are subject to selection bias and placebo effects.

CRFA was also compared with corticosteroid injections for the treatment of knee pain in two randomized crossover trials by Davis et al. A total of 151 patients with pain ≥ 6 months who did not respond to conservative treatment were enrolled in the studies and randomized to CRFA or intra-articular corticosteroid injection (IACS). At 6 months, numeric rating scale (NRS) score for CRFA was significantly less than for IACS injections (2.5 ± 2.3 versus 5.9 ± 2.2, respectively). The pain reduction ≥ 50% (from NRS scores) was statistically greater in the CRFA than the IACS group, 74.1% versus 16.2%, respectively (p < 0.0001). At 12 months, 65% of patients who were originally treated with CRFA reported > 50% pain reduction with a significant 4.2-point drop on NRS (baseline NRS: 7.3 ± 1.2; 12-month NRS: 3.1 ± 2.7). CRFA management of knee pain occurs sooner than IACS injections, and its beneficial effects can last up to 12 months. Studying the impact of CRFA is of great interest but has encountered multiple challenges. In the aforementioned study, patients were taking opioids for different reasons (back pain, hip pain, etc.), so it was difficult to assess the duration of opioid use before CRFA treatment, and study cohorts are small. At 18 months, 12 of 25 subjects (48.0%) continued to report ≥ 50% pain relief, and 20 patients (80.0%) reported improvement from their chronic pain after CRFA. At 24 months, 11 of 18 patients experienced ≥ 50% pain relief.
These data imply that the benefits of CRFA may extend up to 24 months in some patients. No adverse events were reported at 18 and 24 months.

CRFA was also compared with HA injections in a randomized controlled trial. Chen et al enrolled 177 patients in a randomized crossover study with follow-ups at 1, 3, 6, and 12 months. At 6 months, the CRFA group experienced a significantly greater degree of pain relief compared with HA injections with NRS scores of 2.7 and 5.0, respectively ($p < 0.0001$). From the study’s findings at 6 months, CRFA achieved faster pain relief in patients with knee pain compared with HA injections. At 12 months, both treatments demonstrated a significant decrease in NRS score from the 6-month mark (CRFA NRS was 2.8 and HA injection NRS was 3.0) ($p < 0.0001$).

These two clinical trials suggest a higher effectiveness of CRFA in treating symptoms related to knee arthritis compared with other conservative measures; however, there is some heterogeneity in the response described for all treatments. Patients are currently deemed candidates for CRFA based on responding successfully to the nerve block with at least 50% pain decrease used as a discriminator, but there are also nonresponders to CRFA among these patients. More research is needed to understand the ability of nerve blocks and other patient characteristics to predict response to CRFA, to improve patient pre-selection for this procedure. The pathophysiology of OA is complex and multifactorial, and it requires a higher order of phenotyping that would significantly reduce trial and error in the clinic and may lead to better nonsurgical outcomes.

**Hip Osteoarthritis**

The most common cause of chronic hip pain with advancing age is OA that is also associated with stiffness, restriction of mobility, atrophy of muscles, impaired ambulation, and microinstability. About 12 to 14.3% of adults > 60 years of age have hip pain. Other important causes of chronic pain in the hip include rheumatoid arthritis, acetabular labral tears, osteonecrosis, posttraumatic arthritis, chronic infectious coxarthrosis, avascular necrosis, and persistent postoperative pain following total hip arthroplasty (THA).

Conservative management strategies including education regarding activity and weight loss, physical therapy, assistive devices, and analgesics (acetaminophen, NSAIDs, opioids) are often used to provide pain relief in patients with pain from hip OA, but these interventions confer only temporary benefits and often lack efficacy. Nonopioid analgesics may have adverse effects, such as gastrointestinal bleeding and renal failure. Minimally invasive interventional techniques, such as intra-articular injections with corticosteroids, visco-supplementation, and regenerative therapies, often fail to provide long-term pain relief. Patients who do not respond to conservative treatments usually undergo THA, which has a high failure rate (5–15%), significant cost (average cost of THA and revision hip surgery is $13,339 and $21,224, respectively), and substantial morbidity including persistent postsurgical pain in 7 to 28% of patients, and mortality.

“Hip pain” is difficult to define topographically. Patients with pain related to pathology in the hip joint present with pain in one or more of these locations: groin, anterolateral thigh, gluteal region, and occasionally referred pain below the knee. Potential pain generators include intra-articular and extra-articular structures, such as ligaments, labrum, cartilage, synovium, bone, bursae, tendons, and nerves. Among the various locations, groin pain is by far the most common, and limitation of internal rotation on physical examination usually suggests intra-articular pathology.

### Technique

The innervation of the hip joint is complex, compartmentalized, and originates from multiple sources. The anteromedial hip is supplied by the articular sensory branches of the obturator nerve, and the anterior hip joint capsule is innervated by the sensory articular branches of the femoral nerve (Fig. 4). The posterior hip is supplied by the articular sensory branches of the sciatic nerve, and the posteromedial hip joint capsule is innervated by the sensory articular branches of the nerve to the quadratus femoris muscle. Because the anterior capsule has a high concentration of nociceptors and mechanoreceptors, it is the ideal anatomical region for CRFA.

#### Diagnostic Nerve Block Procedure

Diagnostic nerve blocks are performed to determine candidacy for CRFA. Patients lie supine, and 0.5 to 1.0 mL lidocaine is injected at two positions: the 12 o’clock position of the acetabular dome to target the femoral sensory nerve branch.
(es), and the acetabular incisura (junction of the ischium and inferior pubic ramus) to target the obturator branch. If the patient reports at least a 50% reduction in the subjective Likert scale pain score 15 to 20 minutes after the nerve block procedure, ablation is performed 3 to 4 weeks later. 59

Radiofrequency Ablation Procedure
Patients lie supine upon the fluoroscopy table, with the hip, inguinal region, and medial thigh exposed and steriley prepped. They are moderately sedated with 1 to 2 mg IV midazolam or 25 to 100μg IV fentanyl, as needed, and provided with supplementary oxygen via nasal cannula. To ensure adequate conduction of the CRFA, a grounding pad is placed ipsilateral to the target joint, avoiding major scar tissue, bony prominences, metal prostheses, EKG electrodes, and areas of possible edema. Then 1 to 2 mL 1% lidocaine is injected superficially at each target site for CRFA.

For the obturator nerve, the inguinal ligament serves as the anatomical landmark. First, a detailed evaluation of the femoral neurovascular bundle is performed under US, and the proximal medial thigh skin is marked with a line indicating the location of the major vessels. A scout AP pelvis view is performed to evaluate obturator foramina for symmetry. For maximal ablation, the acetabular incisura is targeted for obturator nerve ablation. The hip, inguinal area, and medial thigh are exposed and steriley prepared. A 25G needle is inserted posterior to the medial border of the femoral artery and advanced deep to the femoral neurovascular sheath, with great care to avoid the femoral artery, vein, and nerve, until the needle makes bony contact at the acetabular incisura. Local anesthesia is delivered along the tract. The CRFA introducer (4mm active tip) is advanced in a similar fashion and kept in intermittent contact with the anterior ischial surface to avoid the needle traveling superficially. Following aspiration to confirm no blood return, 0.5 to 1 mL contrast can be injected for correct anatomical confirmation. Motor nerve activity is excluded with testing (2 Hz at 1 mA). Once cleared, 0.5 to 1 mL lidocaine is injected for deep local anesthesia followed by two successive ablations (at the incisura and 3 mm distal to it) (► Figs. 5 and 6).

For the sensory branches of the femoral nerve, the target site for ablation is the 12 o’clock superior acetabular position. The entry site is located 2 cm lateral to the femoral artery.

Fig. 5 Top illustration shows proper probe location for the treatment of the femoral nerve branch at ~ 12 o’clock in the acetabular dome. Bottom two images show the respective location near the incisura, treating branches of the obturator nerve.
Superficial local anesthesia is applied to the area, and the needle is inserted until bony contact is made at the osseous acetabulum. The CRFA introducer is inserted along the anesthetized tract, until bony contact is made with the underlying acetabular plate. Motor neuron stimulation is performed and when excluded, 1 to 2 mL deep local anesthesia is injected. The CRFA probe is placed, and the sensory nerves are ablated (Figs. 5 and 6).

**Efficacy of CRFA for Treating Hip OA Pain**

In a systematic review of 16 publications (6 case reports and 7 retrospective and 3 prospective case series) that used TRFA to treat all sources hip pain including OA, TRFA patients had significant reduction in pain at 8 days to 3 years after the procedure; analgesic benefit varied between 30% and 90% from baseline scores. Kapural et al performed 52 fluoroscopic and US-guided CRFA procedures in 23 patients who had hip pain. They found that significant reduction in hip pain was achieved for up to 320 days after the first ablation and up to 300 days after the second ablation, with VAS score decreasing from 7.61 ± 0.9 to 2.25 ± 1.4 after the second ablation. In a pilot prospective study at our institution (unpublished data), 11 hip pain patients’ overall VAS score decreased from 8.3 ± 1.1 at baseline to 2.5 ± 0.5 at 6 months after CRFA.

Unlike for knee OA, no studies have compared CRFA with other conservative treatments for hip OA. Further research must be performed comparing other conservative modalities with CRFA to further understand this alternative method of treating pain in different clinical settings, such as advanced arthrosis and persistent pain after THA.

**Shoulder Osteoarthritis**

The four most common causes of shoulder pain include rotator cuff and glenohumeral disorders, acromioclavicular joint pathology, and referred neck pain. Shoulder OA is responsible for 4% of shoulder pain and has severely debilitating symptoms of pain and limited range of motion. As age increases from 40 to 80 years, shoulder OA prevalence increases from 1.8% to 27.5%, respectively. Patients who exercise excessively or practice occupations that require over-the-head lifting can also accelerate shoulder OA. Other risk factors include surgeries such as arthroscopic Bankart repairs, fractures, rotator cuff pathology, scapular dysmorphology, inflammatory arthritis, and avascular necrosis of the humeral head.

The goals of conservative treatments are to treat pain and improve range of motion before disuse causes muscle atrophy. Physical therapy is a useful modality that helps patients gain mobility and isometric strength. Medical management with NSAIDs and acetaminophen helps relieve pain and inflammation with relatively great efficacy lasting up to 3 months. Intra-articular injections for shoulder OA have been studied, but not as extensively as knee and hip OA, and there is no level 1 and 2 evidence. For instance, Merolla et al compared injections with HA and corticosteroid shots in 84 patients, showing that VAS pain scores significantly decreased from 6.1 ± 0.9 to 3.65 ± 0.9 at 6 months in the HA group (p < 0.05) and a nonsignificant decrease from 6.25 ± 1.7 to 5.94 ± 1.2 at 6 months in the corticosteroid group (p = 0.069). A more recent prospective study demonstrated a significant decrease in shoulder pain at 6 months.
after HA injection with physical therapy, compared with patients treated with physical therapy only.\textsuperscript{70}

**Technique**

The innervation of the shoulder joint is intricate. The suprascapular nerve innervates most of the posterior shoulder capsule, subacromial bursa, and coracoacromial and acromioclavicular ligaments (\textit{\textsuperscript{Fig. 7}}). The axillary nerve innervates the posterior inferior and lateral aspects of the glenohumeral capsule. The lateral pectoral nerve innervates the anterosuperior region of the shoulder (anterior border of the subacromial bursa, the coracoacromial ligaments, and the anterior joint capsule). The highest density of nociceptors and mechanoreceptors was reported in the subacromial bursa and anterior glenohumeral capsule/ligaments.\textsuperscript{71}

**Diagnostic Nerve Block Procedure**

Patients undergo diagnostic nerve injection at three target sites to determine candidacy for CRFA (\textit{\textsuperscript{Fig. 7}}). The suprascapular nerve is targeted along the posterior superior third of the glenoid rim, \(\sim 2\) to 3 mm away from the articular surface (\textit{\textsuperscript{Fig. 7a, A}}), the axillary nerve is targeted at the inferolateral border of the greater tuberosity (\textit{\textsuperscript{Fig. 7a, B}}), and the lateral pectoral nerve is targeted at the midpoint of the coracoid process (\textit{\textsuperscript{Fig. 7b, C}}). If the patient reports at least 50% reduction in the subjective Likert scale pain score 15 to 20 minutes after the nerve block procedure, ablation is performed 3 to 4 weeks later.\textsuperscript{59}

**Radiofrequency Ablation Procedure**

To target the posterior shoulder, the patient is positioned in the prone position. The hand ipsilateral to the affected shoulder is internally rotated (pronated forearm). The grounding pad is applied to the patient’s ipsilateral flank. The patient’s posterior shoulder is steriley prepped for the procedure.

The suprascapular nerve is targeted at two different sites. To target the first suprascapular nerve site, the C-arm is then rotated 15 to 45 degrees from the AP position toward the affected shoulder to find the posterior border of the glenoid process to profile the glenohumeral joint. A 15-degree caudal tilt is added to visualize the glenoid in full view (\textit{\textsuperscript{Figs. 8a and 9a}}). Local anesthesia is then administered in the expected location of the suprascapular nerve, at the junction of the upper and middle thirds of the glenoid rim, near the articular surface, lateral and superior to the spinoglenoid notch. 17G introducer is inserted until it contacts the superior glenoid rim 2 to 3 mm medial to the articular surface to avoid inserting the needle into the joint space. The introducer stylet is removed, the CRFA probe (2mm active tip) is placed, and motor neurons are excluded via nerve stimulation. The rotator cuff muscles should also be observed for twitching or movement. If there are any positive responses to motor nerve stimulation, the introducer should be moved laterally, increasing the distance from the suprascapular motor trunk. After motor nerve exclusion, deep local anesthesia is injected, and the sensory nerve is ablated for 150 seconds. The second suprascapular nerve site is 3 to 4 mm inferior to the first position (posterior osseous rim of

\textit{\textsuperscript{Fig. 7}} Schematics demonstrate the respective (a) posterior and (b) anterior nerves about the shoulder joint. The anatomical course of the suprascapular nerve and branches along the superior aspect of the glenoid rim is marked as A. B depicts the course of the axillary nerve branches along the greater tuberosity of the humerus. The course of the lateral pectoral major branch in the region of the coracoid process along the anterior shoulder is marked as C.

\textit{\textsuperscript{Fig. 8}} (a) Radiofrequency ablation probe placements for the treatment of the suprascapular nerve branches. (b) Needle placements at the branches of the axillary nerve. (c) Treatment of the lateral pectoral nerve.
the glenoid fossa, lateral to the spinoglenoid notch (Figs. 8a and 9a). The same skin entry site should be used, repositioning the introducer, and the same steps are taken to ablate the nerve for 150 seconds.

There are two sites for the axillary nerve. The C-arm angles are the same, but the image is centered over the humeral head. For the first axillary nerve site, local anesthesia is injected superficially. The introducer is inserted at the outermost aspect of the greater tuberosity above the level of the surgical neck (Figs. 8b and 9b). The introducer is advanced until it contacts the cortex. Motor nerve stimulation is initiated while also observing for movement in the deltoid and teres minor muscles. If detected, the introducer must be repositioned cranially and laterally to distance it from the axillary motor nerve trunk. Once excluded, the sensory nerve can be ablated. For the second axillary nerve site, the probe is removed and the stylet replaced. Using the same skin entry site, the introducer is positioned 3 to 4 mm inferior to the greater tubercle, where it tapers into the humeral diaphysis while remaining on the most lateral humeral border. The same steps are taken to ablate this second axillary nerve (Figs. 8b and 9b).

There is only one ablation site for the lateral pectoral nerve (Figs. 8c and 9c). The patient is turned from prone to supine position on the table. The patient’s anterior shoulder is steriley prepped. The grounding pad’s adherence should be confirmed again on the patient’s ipsilateral flank, in case it was moved or dislodged while the patient was being repositioned. To visualize the shoulder girdle, the procedure begins with the C-arm rotated 15 degrees toward the affected shoulder from the posterolateral view, and then rotated medially until the coracoid process superimposes medially upon the glenohumeral joint. Then a 15-degree cephalic tilt is applied to give the coracoid process a “thumbs-down” appearance. The introducer is inserted at the midpoint of the coracoid process and advanced until it contacts the cortex. Because the sensory branches of the lateral pectoral nerve are superficial, the introducer must be at least 2 cm deep to avoid skin burns during ablation. Motor neuron stimulation is performed while observing the pectoralis major muscle. If there is a positive response, the introducer should be moved medially to avoid the lateral pectoral motor trunks. Once motor nerves are excluded, deep local anesthesia is injected, and ablation is performed.

### Efficacy of CRFA for Treating Shoulder OA Pain

Little evidence supports CRFA for shoulder pain from OA. Eckmann et al performed a retrospective study that investigated CRFA that targeted the suprascapular, axillary, and lateral pectoral nerve in patients with chronic intractable shoulder pain. At the first follow-up visit of 3 months, all 10 patients reported a decrease in mean NRS pain score from 6.0 to 1.1 ($p = 0.001$). Six of 10 patients who were followed until 6 months reported > 50% pain relief at the second time point. Four of these patients had shoulder OA, and the remaining two patients had rotator cuff tendinopathy.

Other studies have looked at TRFA for shoulder pain, but not shoulder pain from OA specifically. Gabrhelik et al retrospectively studied 28 patients who received pulsed TRFA to the suprascapular nerve and compared local anesthetic and pulsed TRFA with and without corticosteroid injection. They found that both groups had significant reduction in VAS scores at 6 months (corticosteroid group: 4.6; 95% confidence interval [CI], 3.7–5.6 versus 2.6; 95% CI, 1.5–3.6; non-corticosteroid group: 5.1; 95% CI, 4.5–6.7 versus 1.6; 95% CI, 0.5–2.6) with no statistically significant difference between the corticosteroid and non-corticosteroid group ($p > 0.05$). From the current literature, little evidence supports CRFA treatment for shoulder pain from OA. More studies are needed to evaluate its efficacy for shoulder OA and other etiologies of shoulder pain, and also to compare its efficacy with other treatment modalities including HA and corticosteroid injections.

### Conclusion

Thermal ablation techniques such as CRFA have evolved as alternative treatment methodology for moderate to severe forms of symptomatic knee OA among patients who have failed conservative treatments. CRFA treatment of knee pain is supported by prospective clinical trials that report sustained efficacy for up to 2 years, which is longer than conventional treatments such as corticosteroid and HA injections. The limited number of studies evaluating CRFA for the treatment of symptomatic advanced hip OA suggests
benefit for reducing pain. However, no study has directly compared CRFA with other conservative modalities in this setting. The limited experience of CRFA applied to the treatment of general shoulder pain suggests potential utility in applications related to shoulder OA pain, although prospective clinical trials in patients with shoulder OA are needed to understand the extent and duration of pain relief. OA remains a growing problem that will affect many adults, and CRFA is a promising tool that will likely be used with other treatment options in the management of symptomatic OA.

Conflict of Interest
None declared.

References
5 Chillemi C, Franceschini V. Shoulder osteoarthritis. Arthritis (Egypt) 2013;33:70231
7 Kompel AJ, Roemer FW, Murakami AM, Diaz LE, Crema MD, Guermazi A. Intra-articular corticosteroid injections in the hip and knee: perhaps not as safe as we thought? Radiology 2019;293(03):656–663
13 Gonzalez FM. Cooled radiofrequency genicular neurotomy. Tech Vasc Interv Radiol 2020;23(04):100706
37 Davis T, Loudermilk E, DePalma M, et al. Prospective, multicenter, randomized, crossover clinical trial comparing the safety and effectiveness of cooled radiofrequency ablation with...
49 Hip and Knee Replacements: Canadian Joint Replacement Registry 2013. May 6, 2017; Available at: https://secure.chi.ca/estore/productFamily.htm?pf=PCF2209&lang=en&media=0
52 Grayson CW, Decker RC. Total joint arthroplasty for persons with osteoarthritis. PM R 2012;4(5, Suppl):S97–S103